✦ LIBER ✦

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

✍ Scribed by Alan N. Gordon; Margaret Tonda; Steven Sun; Wayne Rackoff

Book ID: 113959455
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 305 KB
Volume: 95
Category: Article
ISSN: 0090-8258
DOI: 10.1016/j.ygyno.2004.07.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

BRCA Mutation Status and Determinant of

BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin

✍ Safra, T.; Borgato, L.; Nicoletto, M. O.; Rolnitzky, L.; Pelles-Avraham, S.; Gev 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 385 KB

Phase II, Open-Label, Randomized, Multic

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

✍ Kaye, S. B.; Lubinski, J.; Matulonis, U.; Ang, J. E.; Gourley, C.; Karlan, B. Y. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 165 KB